Artiva Biotherapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Artiva Biotherapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $251.0K | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $33.49M | Mar 24, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $32.92M | Mar 24, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($83.87M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($65.37M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($28.72M) | Mar 24, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($89.81M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($67.28M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($30.67M) | Mar 24, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.54M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $50.33M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $50.25M | Mar 24, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($76.75M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($55.03M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($47.43M) | Mar 24, 2025 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.59M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $642.0K | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $3.26M | Mar 24, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $130.94M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $209.58M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $105.11M | Mar 24, 2025 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.97M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $22.94M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $50.72M | Mar 24, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.97M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $186.64M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | ($162.02M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | ($140.70M) | Mar 24, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($330.55M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($246.68M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($181.31M) | Mar 24, 2025 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.70M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $40.24M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $53.50M | Mar 24, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (35) | Mar 24, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (35) | Mar 24, 2025 |